Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (243)	7/2/2003 7:30:26 PM
From: Icebrg	Read Replies (2) \| Respond to of 590

Miljenko Yes, if the results they have not yet disclosed are very good, they might want to take in ABX-EGF. (I remember how disappointed you were after ASCO). Which ABGX will not sell because that is almost the "only" thing they have. To ABGX the production facilities are less of an advantage. They will cost them a lot of money. Which they don't have enough of. Interesting, if this should turn out to be true, that both the EPO-boosters want to expand into real cancer treatments. A bid for ANGX would also to some extent explain Amgen's eagerness to take full control over Genmab's HuMax-IL15. To get that out of the way, if they wanted the mAb. But ABGX's external mAb-business will not fit into the picture. Not at all. No-one would like to have Amgen seeing everything they do and try to develop. One solution would be for AMGN to sell the mice to someone else. Perhaps to Protein Design Lab. They seem to be slipping behind and would most probably be very happy to lay their hands on a more modern technology. Erik

To: Miljenko Zuanic who wrote (243)	7/2/2003 7:34:43 PM
From: keokalani'nui	Respond to of 590

Some pretty serious volume, and OI, in the July calls today. finance.yahoo.com

To: Miljenko Zuanic who wrote (243)	7/4/2003 9:02:08 AM
From: nigel bates	Read Replies (1) \| Respond to of 590

AMGN will also have in-house mAb generation and validation capacity, which can not be neglected. ABGX licensors will be left behind... And don't forget the deals with LEXG, CRGN (& MDS Proteomics), the "Antigen Target Sourcing Contracts". These are just starting to get into the clinic, and could well do so a lot faster with AMGN financial muscle behind them. I'm sceptical regarding a takeover too, but there are certainly reasons for AMGN to look at it.